RNA vs NGNE

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 11, 2026

RNA

51.6
AI Score
VS
RNA Wins

NGNE

31.6
AI Score

Investment Advisor Scores

RNA

52score
Recommendation
HOLD

NGNE

32score
Recommendation
AVOID NEW MONEY

AI Analyst Insights

Detailed Metrics Comparison

Metric RNA NGNE Winner
Forward P/E 0 0 Tie
PEG Ratio 0 0 Tie
Revenue Growth -21.9% 0.0% NGNE
Earnings Growth 0.0% 0.0% Tie
Tradestie Score 51.6/100 31.6/100 RNA
Profit Margin -184.1% 0.0% NGNE
Beta 1.00 1.00 Tie
AI Recommendation HOLD AVOID NEW MONEY RNA

Relative Price Performance (Last 90 Days)

RNA 1M: +4.4% · 3M: -34.4% NGNE 1M: +18.6% · 3M: -28.2%

Current Technical Phase

RNA

Markdown
Sell / avoid

Price below a falling SMA50 (slope -17.8%), weak momentum, RSI 42

RSI (14): 41.7 · Price: $8.09

NGNE

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 46

RSI (14): 46.1 · Price: $25.57

Fundamentals Snapshot

Metric RNA NGNE
Market Cap — —
Forward P/E -1.4 -4.4
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth -0.2% 0.0%
Gross Margin -0.6% —
Operating Margin -7.5% 0.0%
EPS -5.44 -5.16
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, RNA is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.